NSG 533
EXAM 1
Advanced Pharmacology
Actual Questions with Verified Answers
Wilkes University
Pass the Exam with Confidence
What You Will Get:
➢100 Exam Questions w/ Answers
➢Expert Rationales included.
➢Exam 1 Comprehensive Study Guide
, PREVIEW ACCESS
Preview Pages Below
Get the Complete PDF
After Purchase
“ If you require further clarification or in need of any study
resources, feel free to Message me.
”
Your complete study resource becomes available after purchase.
,Table of Contents
NSG 533 Exam 1 ................................................................................ 2
NSG 533 Exam 1 ............................................................................. 25
NSG 533 Exam 1 Focused Study Guide .............................. 50
NSG 533 Exam 1
Question 1
A patient is diagnosed with Helicobacter pylori infection. Which regimen represents the
standard clarithromycin triple therapy?
A) Clarithromycin 500mg BID + amoxicillin 1g BID + PPI BID
B) Clarithromycin 500mg BID + metronidazole 500mg TID + PPI BID
C) Amoxicillin 1g BID + clarithromycin 500mg BID + metronidazole 500mg BID + PPI
BID
D) Both A and B are acceptable clarithromycin triple therapy regimens
Correct Answer: D
Rationale: Clarithromycin triple therapy consists of clarithromycin 500mg BID plus a PPI
BID, with EITHER amoxicillin 1g BID OR metronidazole 500mg TID as the third agent.
Option A represents the amoxicillin-based regimen; Option B represents the
metronidazole-based regimen (used in penicillin-allergic patients or areas with high
macrolide resistance). Option C describes a nonbismuth-based quadruple therapy, not
triple therapy.
Question 2
, Which of the following describes the nonbismuth-based quadruple therapy for H.
pylori? (Select all that apply)
A) Amoxicillin 1g BID
B) Clarithromycin 500mg BID
C) Metronidazole 500mg BID
D) PPI BID
E) Bismuth subsalicylate 300mg QID
Correct Answer: A, B, C, D
Rationale: Nonbismuth-based quadruple therapy (also called concomitant therapy)
includes four medications: amoxicillin 1g BID, clarithromycin 500mg BID, metronidazole
500mg BID, and a PPI BID. This regimen does NOT include bismuth subsalicylate—that
is reserved for bismuth quadruple therapy. The quadruple approach is used when
clarithromycin resistance is a concern or as first-line in some guidelines.
Question 3
A patient with a documented penicillin allergy requires H. pylori treatment. Which
alternate regimen should be recommended?
A) Continue standard clarithromycin triple therapy with amoxicillin; penicillin allergy is
rarely true
B) Bismuth quadruple therapy: bismuth subsalicylate 300mg QID + metronidazole 250–
500mg QID + tetracycline 500mg QID + PPI BID
C) Nonbismuth-based quadruple therapy with amoxicillin substituted for azithromycin
D) PPI monotherapy for 14 days
Correct Answer: B
Rationale: In patients with true penicillin allergy, bismuth quadruple therapy is the
recommended alternative. This regimen includes bismuth subsalicylate 300mg QID,
metronidazole 250–500mg QID, tetracycline 500mg QID, and a PPI BID. Tetracycline is
used instead of amoxicillin, and the bismuth provides additional mucosal protection and
antimicrobial activity. Option D (PPI monotherapy) would not eradicate H. pylori.
EXAM 1
Advanced Pharmacology
Actual Questions with Verified Answers
Wilkes University
Pass the Exam with Confidence
What You Will Get:
➢100 Exam Questions w/ Answers
➢Expert Rationales included.
➢Exam 1 Comprehensive Study Guide
, PREVIEW ACCESS
Preview Pages Below
Get the Complete PDF
After Purchase
“ If you require further clarification or in need of any study
resources, feel free to Message me.
”
Your complete study resource becomes available after purchase.
,Table of Contents
NSG 533 Exam 1 ................................................................................ 2
NSG 533 Exam 1 ............................................................................. 25
NSG 533 Exam 1 Focused Study Guide .............................. 50
NSG 533 Exam 1
Question 1
A patient is diagnosed with Helicobacter pylori infection. Which regimen represents the
standard clarithromycin triple therapy?
A) Clarithromycin 500mg BID + amoxicillin 1g BID + PPI BID
B) Clarithromycin 500mg BID + metronidazole 500mg TID + PPI BID
C) Amoxicillin 1g BID + clarithromycin 500mg BID + metronidazole 500mg BID + PPI
BID
D) Both A and B are acceptable clarithromycin triple therapy regimens
Correct Answer: D
Rationale: Clarithromycin triple therapy consists of clarithromycin 500mg BID plus a PPI
BID, with EITHER amoxicillin 1g BID OR metronidazole 500mg TID as the third agent.
Option A represents the amoxicillin-based regimen; Option B represents the
metronidazole-based regimen (used in penicillin-allergic patients or areas with high
macrolide resistance). Option C describes a nonbismuth-based quadruple therapy, not
triple therapy.
Question 2
, Which of the following describes the nonbismuth-based quadruple therapy for H.
pylori? (Select all that apply)
A) Amoxicillin 1g BID
B) Clarithromycin 500mg BID
C) Metronidazole 500mg BID
D) PPI BID
E) Bismuth subsalicylate 300mg QID
Correct Answer: A, B, C, D
Rationale: Nonbismuth-based quadruple therapy (also called concomitant therapy)
includes four medications: amoxicillin 1g BID, clarithromycin 500mg BID, metronidazole
500mg BID, and a PPI BID. This regimen does NOT include bismuth subsalicylate—that
is reserved for bismuth quadruple therapy. The quadruple approach is used when
clarithromycin resistance is a concern or as first-line in some guidelines.
Question 3
A patient with a documented penicillin allergy requires H. pylori treatment. Which
alternate regimen should be recommended?
A) Continue standard clarithromycin triple therapy with amoxicillin; penicillin allergy is
rarely true
B) Bismuth quadruple therapy: bismuth subsalicylate 300mg QID + metronidazole 250–
500mg QID + tetracycline 500mg QID + PPI BID
C) Nonbismuth-based quadruple therapy with amoxicillin substituted for azithromycin
D) PPI monotherapy for 14 days
Correct Answer: B
Rationale: In patients with true penicillin allergy, bismuth quadruple therapy is the
recommended alternative. This regimen includes bismuth subsalicylate 300mg QID,
metronidazole 250–500mg QID, tetracycline 500mg QID, and a PPI BID. Tetracycline is
used instead of amoxicillin, and the bismuth provides additional mucosal protection and
antimicrobial activity. Option D (PPI monotherapy) would not eradicate H. pylori.
